Eagle Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Net Income	35.64	-8.63	11.99	14.31	31.9	51.94	81.45	2.57	-19.64	-9.89	Upgrade
Depreciation & Amortization	13.27	4.81	4.77	4.65	3.67	3.75	1.59	0.11	0.1	0.14	Upgrade
Share-Based Compensation	16.45	19.56	24.76	22	19.08	15.43	9.77	4.05	0.61	0.32	Upgrade
Other Operating Activities	-14.66	12.49	7.99	15.02	-2.27	-12.2	-39.6	-16.45	3.42	-0.28	Upgrade
Operating Cash Flow	50.7	28.22	49.5	55.99	52.38	58.92	53.21	-9.72	-13.84	-5.88	Upgrade
Operating Cash Flow Growth	79.67%	-42.99%	-11.59%	6.88%	-11.09%	10.74%	-	-	-	-	Upgrade
Capital Expenditures	-0.18	-0.32	-0.75	-0.78	-0.13	-4.44	-1.59	-1.88	-0.05	-0.04	Upgrade
Acquisitions	-74.15	0	0	0	0	-0.75	-44.21	0	0	0	Upgrade
Change in Investments	-12.5	-5	-17.5	0	0	0	0	0	-20	1.5	Upgrade
Investing Cash Flow	-86.83	-5.32	-18.25	-0.78	-0.13	-5.19	-45.8	-1.88	-20.05	1.46	Upgrade
Share Issuance / Repurchase	-16.26	-18.82	-31.35	-17.7	-64.49	-39.45	-33.38	55.81	46.13	0	Upgrade
Debt Issued / Paid	11.4	-8	-5	-6.33	-3.75	47.56	0	0	0	0	Upgrade
Other Financing Activities	-1.36	-1.58	-1.53	-0.2	-19.88	-	-0.29	-	0.02	9.81	Upgrade
Financing Cash Flow	-6.21	-28.39	-37.87	-24.23	-88.12	8.1	-33.67	55.81	46.15	9.81	Upgrade
Net Cash Flow	-42.34	-5.5	-6.62	30.98	-35.87	61.84	-26.26	44.21	12.27	5.39	Upgrade
Free Cash Flow	50.52	27.9	48.75	55.21	52.25	54.48	51.62	-11.6	-13.89	-5.92	Upgrade
Free Cash Flow Growth	81.11%	-42.78%	-11.70%	5.66%	-4.10%	5.55%	-	-	-	-	Upgrade
Free Cash Flow Margin	15.96%	16.26%	25.96%	28.18%	24.50%	23.02%	27.24%	-17.51%	-72.72%	-43.28%	Upgrade
Free Cash Flow Per Share	3.91	2.14	3.62	4.01	3.54	3.61	3.32	-0.76	-1.40	-1.95	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).